Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
17/06/2024 | 14:30 | PR Newswire (US) | BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
08/06/2024 | 00:09 | PR Newswire (US) | KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
07/06/2024 | 15:00 | PR Newswire (US) | BioMarin Presents New Phase 3, Four-Year Data Underscoring Long-Term Safety and Efficacy of ROCTAVIAN® (valoctocogene roxaparvovec-rvox) at International Society on Thrombosis and Haemostasis 2024 Congress | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
05/06/2024 | 01:28 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
04/06/2024 | 16:18 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
24/05/2024 | 22:02 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
22/05/2024 | 22:33 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
08/05/2024 | 14:00 | PR Newswire (US) | BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
04/05/2024 | 22:00 | PR Newswire (US) | New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
24/04/2024 | 22:03 | PR Newswire (US) | BioMarin Reports Record Financial Results for the First Quarter 2024 | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
10/04/2024 | 14:00 | PR Newswire (US) | BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
12/03/2024 | 13:30 | PR Newswire (US) | New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
07/03/2024 | 14:30 | PR Newswire (US) | BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
01/03/2024 | 15:00 | PR Newswire (US) | BioMarin Scheduled to Participate in March Investor Conferences | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
26/02/2024 | 19:34 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
22/02/2024 | 22:03 | PR Newswire (US) | BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
12/02/2024 | 21:24 | Edgar (US Regulatory) | Form 5 - Annual statement of changes in beneficial ownership of securities | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
09/02/2024 | 23:46 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
08/02/2024 | 14:00 | PR Newswire (US) | BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
06/02/2024 | 14:30 | PR Newswire (US) | BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
26/01/2024 | 17:49 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
03/01/2024 | 14:00 | PR Newswire (US) | BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
20/12/2023 | 22:05 | PR Newswire (US) | BioMarin Announces Governance Enhancements and Value Creation Initiatives | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
28/11/2023 | 14:30 | PR Newswire (US) | BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
02/11/2023 | 21:09 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
02/11/2023 | 19:53 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
01/11/2023 | 21:05 | PR Newswire (US) | BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
01/11/2023 | 21:02 | PR Newswire (US) | BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
20/10/2023 | 22:54 | Dow Jones News | BioMarin Pharmaceutical's Achondroplasia Treatment Gets FDA Approval for All Pediatric Patients | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |
20/10/2023 | 22:05 | PR Newswire (US) | U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia | NASDAQ:BMRN | BioMarin Pharmaceutical Inc |